Black Diamond Therapeutics, Inc.
BDTX$114M
Micro CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaCAMBRIDGE24 employees
Drugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
7wMarket Overview
Stock performance and key metrics
BDTX News
Catalyst Timeline
1 upcoming, 2 past
Drug Pipeline
silevertinib (BDTX-1535) monotherapy
Non-Small Cell Lung Cancer
silevertinib in combination with temozolomide
Glioblastoma (GBM)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
silevertinib (BDTX-1535) monotherapy | Phase 2 | Non-Small Cell Lung Cancer | - | - |
silevertinib in combination with temozolomide | Phase 2 | Glioblastoma (GBM) | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply